ANGO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ANGO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
AngioDynamics has the Profitability Rank of 3. It has had trouble to make a profit.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is rated on a scale of 1 to 10 and is based on these factors:
1. Operating Margin %A higher score indicates superior profitability, with companies rated 7 or above considered to have more robust and sustainable profit generation. Conversely, a score of 3 or lower suggests challenges in generating consistent profits.
AngioDynamics's Operating Margin % for the quarter that ended in Nov. 2024 was -6.96%. As of today, AngioDynamics's Piotroski F-Score is 3.
For the Medical Instruments & Supplies subindustry, AngioDynamics's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, AngioDynamics's Profitability Rank distribution charts can be found below:
* The bar in red indicates where AngioDynamics's Profitability Rank falls into.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
The rank is rated on a scale of 1 to 10. A higher score indicates superior profitability, with companies rated 7 or above considered to have more robust and sustainable profit generation. Conversely, a score of 3 or lower suggests challenges in generating consistent profits.
AngioDynamics has the Profitability Rank of 3. It has had trouble to make a profit.
Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.
Profitability Rank is based on these factors:
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
AngioDynamics's Operating Margin % for the quarter that ended in Nov. 2024 is calculated as:
Operating Margin % | = | Operating Income (Q: Nov. 2024 ) | / | Revenue (Q: Nov. 2024 ) |
= | -5.07 | / | 72.845 | |
= | -6.96 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Warning Sign:
Piotroski F-Score of 3 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 8 or 9
Bad or low score = 0 or 1
AngioDynamics has an F-score of 3. It is a bad or low score, which usually implies poor business operation.
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
Warning Sign:
AngioDynamics Inc operating margin has been in a 5-year decline. The average rate of decline per year is -62.5%.
4. Consistency of the profitability
5. Predictability Rank
Thank you for viewing the detailed overview of AngioDynamics's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Warren Jr Nighan | officer: SVP Quality and Regulatory | ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110 |
Stephen A Trowbridge | officer: SVP and General Counsel | 14 PLAZA DRIVE, LATHAM NY 120110 |
James C Clemmer | director, officer: President and CEO | COVIDIEN PLC, 15 HAMPSHIRE STREET, MANSFIELD MA 02048 |
Lorinda Burgess | director | 22 WEST FRONTAG ROAD, NORTHBROOK IL 60093 |
Karen A Licitra | director | C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050 |
Michael E Tarnoff | director | C/O ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110 |
Scott Centea | officer: SVP/GM, VIT | C/O ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110 |
Dave Helsel | officer: SVP Global Operations and R&D | 400 WOOD ROAD, BRAINTREE MA 02184 |
Laura Piccinini | officer: SVP International | C/O ANGIODYNAMICS INC., 14 PLAZA DRIVE, LATHAM NY 12110 |
Wesley Johnson | director | |
Chad Thomas Campbell | officer: SVP/GM, Vascular Access | 140 POKANOKET PATH, WRENTHAM MA 02093 |
Richard C Rosenzweig | officer: SVP and General Counsel | C/O DENTSPLY SIRONA INC., 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277 |
Kevin J Gould | director | 247 WASHINGTON STREET, DUXBURY MA 02332 |
Brent J. Boucher | officer: SVP and GM of Oncology | 14 PLAZA DRIVE, LATHAM NY 12110 |
Michael Greiner | officer: EVP and CFO | C/O VISTAPRINT, 95 HAYDEN AVENUE, LEXINGTON MA 02421 |
From GuruFocus
By GuruFocus News • 10-04-2024
By GuruFocus News • 02-14-2025
By GuruFocus News • 01-31-2025
By GuruFocus News • 01-09-2025
By GuruFocus News • 12-19-2024
By Business Wire • 10-21-2024
By GuruFocus News • 01-08-2025
By Business Wire • 09-03-2024
By Business Wire • 10-23-2024
By GuruFocus News • 01-09-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.